Business Briefs

Emory’s Next Phase of Alzheimer’s Disease Research

Emory's facility and research center is one of very few in the Southeast supported by NIH.

Dr. Allan Levey, director of Emory's Alzheimer's research center.

Based on recent discoveries, investigators with Emory University’s newly renamed Goizueta Alzheimer’s Disease Research Center are expected to soon have several promising biomarker candidates that can pinpoint the development of the disease symptoms a decade or more before the onset of cognitive decline and memory loss. Not only does this allow for earlier detection, but it also makes it possible to create fundamental changes in the treatment of this debilitating disease.

The research is made possible through The Goizueta Foundation’s ongoing support of transformational research in developing treatment for the disease.

“The goal of our research is nothing less than a paradigm shift in the future diagnosis and treatment for Alzheimer’s disease,” said Dr. Allan Levey, director of the Alzheimer’s research center.

“Our research at Emory, and that of other Alzheimer’s investigators, is pointing to an immunological basis for Alzheimer’s disease, and treating neuroinflammation has become a compelling strategy.”

Dr. Jonathan S. Lewin, CEO of Emory Healthcare.

Dr. Jonathan S. Lewin, CEO of Emory Healthcare, said the Alzheimer’s research center is “an integral part of Emory’s overall efforts to advance brain health treatment and research. This gift is a tremendous vote of confidence in Dr. Levey and his continued dedication as a visionary leader in his field.”

The Alzheimer’s research center is part of the Emory Brain Health Center and is one of only a few in the Southeast that are supported by the National Institutes of Health. Alz-heimer’s research centers are working collaboratively to find a treatment for the disease by 2025.

read more: